Conditions: Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 201
Healthy volunteers: no

Brief summary:
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell lung cancer. Eligible patients who have recently started Tarceva treatment will be randomized to one of 3 groups, to receive daily treatment with Verutex, Eritex or Fisiogel cream for 30 days, and the incidence and severity of skin rash will be assessed. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: erlotinib [Tarceva] intervention 2: fusidic acid [Verutex] intervention 3: erythromycin [Eritex] intervention 4: Fisiogel
Intervention descriptions: intervention 1: 150mg po daily intervention 2: topical, daily for 30 days. intervention 3: topical, daily for 30 days. intervention 4: topical, daily for 30 days

Protocol document: